Dexcom (Nasdaq:DXCM) announced that it promoted chief technology officer Jake Leach to the chief operating officer (COO) role.
Leach served as CTO since 2018, leading the company’s research, product development, product management and engineering departments. He joined the company in 2004 to lead the development of sensor electronics for its first commercial continuous glucose monitor (CGM) system.
In the 18 years Leach has been at the company, he has led teams responsible for developing multiple generations of CGMs, including the current-generation G6. Earlier this year, Leach spoke to Drug Delivery Business News about the next-generation Dexcom G7 and other offerings.
Leach’s new role will hold end-to-end responsibility for product at the company. According to a news release, he will drive day-to-day decision-making and resource allocation across all product-facing groups.
Additonally, Leach’s responsibilities include overseeing executive leadership functions. That includes global operations, research and development, quality management and regulatory.
“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” said Kevin Sayer, chair, president and CEO. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”
Quentin Blackford, who was Dexcom’s COO for more than four years, left in fall 2021 to become CEO of iRhythm.
